nodes	percent_of_prediction	percent_of_DWPC	metapath
Boceprevir—ABCB1—Lisinopril—systemic scleroderma	0.0633	0.218	CbGbCtD
Boceprevir—CYP3A5—Mycophenolate mofetil—systemic scleroderma	0.0573	0.197	CbGbCtD
Boceprevir—ABCB1—Captopril—systemic scleroderma	0.0474	0.163	CbGbCtD
Boceprevir—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0373	0.128	CbGbCtD
Boceprevir—ABCB1—Prednisone—systemic scleroderma	0.0298	0.103	CbGbCtD
Boceprevir—CTSK—skeletal joint—systemic scleroderma	0.0238	0.156	CbGeAlD
Boceprevir—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0224	0.077	CbGbCtD
Boceprevir—CYP3A4—Prednisone—systemic scleroderma	0.0179	0.0615	CbGbCtD
Boceprevir—CMA1—artery—systemic scleroderma	0.0155	0.101	CbGeAlD
Boceprevir—ABCB1—Methotrexate—systemic scleroderma	0.015	0.0515	CbGbCtD
Boceprevir—CMA1—blood vessel—systemic scleroderma	0.012	0.079	CbGeAlD
Boceprevir—CMA1—Metabolism of Angiotensinogen to Angiotensins—ACE—systemic scleroderma	0.00805	0.0414	CbGpPWpGaD
Boceprevir—CMA1—ACE Inhibitor Pathway—ACE—systemic scleroderma	0.00767	0.0394	CbGpPWpGaD
Boceprevir—CMA1—connective tissue—systemic scleroderma	0.00617	0.0405	CbGeAlD
Boceprevir—CTSV—skin of body—systemic scleroderma	0.00584	0.0383	CbGeAlD
Boceprevir—CMA1—smooth muscle tissue—systemic scleroderma	0.00565	0.0371	CbGeAlD
Boceprevir—CMA1—skin of body—systemic scleroderma	0.00557	0.0366	CbGeAlD
Boceprevir—CTSL—connective tissue—systemic scleroderma	0.00528	0.0347	CbGeAlD
Boceprevir—CTSL—smooth muscle tissue—systemic scleroderma	0.00483	0.0317	CbGeAlD
Boceprevir—CTSL—skin of body—systemic scleroderma	0.00477	0.0313	CbGeAlD
Boceprevir—CTSV—Assembly of collagen fibrils and other multimeric structures—COL1A2—systemic scleroderma	0.00476	0.0245	CbGpPWpGaD
Boceprevir—CTSL—Assembly of collagen fibrils and other multimeric structures—COL1A2—systemic scleroderma	0.00476	0.0245	CbGpPWpGaD
Boceprevir—CMA1—digestive system—systemic scleroderma	0.00446	0.0293	CbGeAlD
Boceprevir—CTSK—connective tissue—systemic scleroderma	0.00398	0.0261	CbGeAlD
Boceprevir—CTSV—lung—systemic scleroderma	0.0039	0.0256	CbGeAlD
Boceprevir—CTSL—digestive system—systemic scleroderma	0.00381	0.025	CbGeAlD
Boceprevir—CMA1—lung—systemic scleroderma	0.00372	0.0244	CbGeAlD
Boceprevir—CTSK—smooth muscle tissue—systemic scleroderma	0.00364	0.0239	CbGeAlD
Boceprevir—CTSL—tendon—systemic scleroderma	0.00363	0.0238	CbGeAlD
Boceprevir—CTSK—skin of body—systemic scleroderma	0.00359	0.0236	CbGeAlD
Boceprevir—CMA1—ACE Inhibitor Pathway—NOS3—systemic scleroderma	0.00357	0.0183	CbGpPWpGaD
Boceprevir—CTSS—connective tissue—systemic scleroderma	0.00349	0.0229	CbGeAlD
Boceprevir—CTSS—Assembly of collagen fibrils and other multimeric structures—COL1A2—systemic scleroderma	0.00325	0.0167	CbGpPWpGaD
Boceprevir—CTSV—Collagen formation—COL1A2—systemic scleroderma	0.00324	0.0167	CbGpPWpGaD
Boceprevir—CTSL—Collagen formation—COL1A2—systemic scleroderma	0.00324	0.0167	CbGpPWpGaD
Boceprevir—CTSV—Activation of Matrix Metalloproteinases—MMP1—systemic scleroderma	0.00319	0.0164	CbGpPWpGaD
Boceprevir—CTSS—smooth muscle tissue—systemic scleroderma	0.00319	0.0209	CbGeAlD
Boceprevir—CTSL—lung—systemic scleroderma	0.00318	0.0209	CbGeAlD
Boceprevir—CTSS—skin of body—systemic scleroderma	0.00315	0.0207	CbGeAlD
Boceprevir—CTSL—Degradation of the extracellular matrix—HSPG2—systemic scleroderma	0.0031	0.0159	CbGpPWpGaD
Boceprevir—CTSV—Degradation of the extracellular matrix—HSPG2—systemic scleroderma	0.0031	0.0159	CbGpPWpGaD
Boceprevir—CMA1—Activation of Matrix Metalloproteinases—MMP1—systemic scleroderma	0.00297	0.0153	CbGpPWpGaD
Boceprevir—CMA1—Degradation of the extracellular matrix—HSPG2—systemic scleroderma	0.00288	0.0148	CbGpPWpGaD
Boceprevir—CTSK—digestive system—systemic scleroderma	0.00287	0.0189	CbGeAlD
Boceprevir—CTSL—Collagen degradation—MMP1—systemic scleroderma	0.00278	0.0143	CbGpPWpGaD
Boceprevir—CTSK—tendon—systemic scleroderma	0.00273	0.0179	CbGeAlD
Boceprevir—CTSK—Activation of Matrix Metalloproteinases—MMP1—systemic scleroderma	0.00265	0.0136	CbGpPWpGaD
Boceprevir—CTSK—Degradation of the extracellular matrix—HSPG2—systemic scleroderma	0.00257	0.0132	CbGpPWpGaD
Boceprevir—CTSS—digestive system—systemic scleroderma	0.00252	0.0165	CbGeAlD
Boceprevir—CTSV—Activation of Matrix Metalloproteinases—MMP2—systemic scleroderma	0.00247	0.0127	CbGpPWpGaD
Boceprevir—CTSK—lung—systemic scleroderma	0.0024	0.0158	CbGeAlD
Boceprevir—CTSS—tendon—systemic scleroderma	0.0024	0.0157	CbGeAlD
Boceprevir—CMA1—ACE Inhibitor Pathway—TGFB1—systemic scleroderma	0.00236	0.0121	CbGpPWpGaD
Boceprevir—CTSK—Collagen degradation—MMP1—systemic scleroderma	0.00231	0.0119	CbGpPWpGaD
Boceprevir—CMA1—Activation of Matrix Metalloproteinases—MMP2—systemic scleroderma	0.0023	0.0118	CbGpPWpGaD
Boceprevir—CTSL—Fluticasone Propionate—Mometasone—systemic scleroderma	0.00227	0.39	CbGdCrCtD
Boceprevir—CTSS—Collagen formation—COL1A2—systemic scleroderma	0.00221	0.0114	CbGpPWpGaD
Boceprevir—CTSL—Collagen degradation—MMP2—systemic scleroderma	0.00215	0.0111	CbGpPWpGaD
Boceprevir—CMA1—Peptide hormone metabolism—ACE—systemic scleroderma	0.00212	0.0109	CbGpPWpGaD
Boceprevir—CTSS—Degradation of the extracellular matrix—HSPG2—systemic scleroderma	0.00211	0.0109	CbGpPWpGaD
Boceprevir—CTSS—lung—systemic scleroderma	0.0021	0.0138	CbGeAlD
Boceprevir—CTSK—Activation of Matrix Metalloproteinases—MMP2—systemic scleroderma	0.00205	0.0105	CbGpPWpGaD
Boceprevir—CTSV—Toll-Like Receptors Cascades—ITGAM—systemic scleroderma	0.00195	0.01	CbGpPWpGaD
Boceprevir—CTSL—Toll-Like Receptors Cascades—ITGAM—systemic scleroderma	0.00195	0.01	CbGpPWpGaD
Boceprevir—CTSV—Activation of Matrix Metalloproteinases—MMP9—systemic scleroderma	0.00186	0.00955	CbGpPWpGaD
Boceprevir—CTSV—Extracellular matrix organization—FBN1—systemic scleroderma	0.00185	0.00953	CbGpPWpGaD
Boceprevir—CTSL—Extracellular matrix organization—FBN1—systemic scleroderma	0.00185	0.00953	CbGpPWpGaD
Boceprevir—CTSK—Collagen degradation—MMP2—systemic scleroderma	0.00178	0.00917	CbGpPWpGaD
Boceprevir—CMA1—Activation of Matrix Metalloproteinases—MMP9—systemic scleroderma	0.00173	0.00887	CbGpPWpGaD
Boceprevir—CMA1—Extracellular matrix organization—FBN1—systemic scleroderma	0.00172	0.00886	CbGpPWpGaD
Boceprevir—CTSL—Collagen degradation—MMP9—systemic scleroderma	0.00162	0.00832	CbGpPWpGaD
Boceprevir—CTSK—Toll-Like Receptors Cascades—ITGAM—systemic scleroderma	0.00161	0.00829	CbGpPWpGaD
Boceprevir—CTSL—MHC class II antigen presentation—HLA-DQB1—systemic scleroderma	0.00157	0.00809	CbGpPWpGaD
Boceprevir—CTSV—MHC class II antigen presentation—HLA-DQB1—systemic scleroderma	0.00157	0.00809	CbGpPWpGaD
Boceprevir—CTSK—Activation of Matrix Metalloproteinases—MMP9—systemic scleroderma	0.00154	0.00791	CbGpPWpGaD
Boceprevir—CTSK—Extracellular matrix organization—FBN1—systemic scleroderma	0.00154	0.0079	CbGpPWpGaD
Boceprevir—CTSV—Degradation of the extracellular matrix—MMP1—systemic scleroderma	0.00141	0.00724	CbGpPWpGaD
Boceprevir—CTSL—Degradation of the extracellular matrix—MMP1—systemic scleroderma	0.00141	0.00724	CbGpPWpGaD
Boceprevir—CTSK—Collagen degradation—MMP9—systemic scleroderma	0.00134	0.00689	CbGpPWpGaD
Boceprevir—CTSS—Toll-Like Receptors Cascades—ITGAM—systemic scleroderma	0.00133	0.00682	CbGpPWpGaD
Boceprevir—CMA1—Degradation of the extracellular matrix—MMP1—systemic scleroderma	0.00131	0.00673	CbGpPWpGaD
Boceprevir—CTSK—MHC class II antigen presentation—HLA-DQB1—systemic scleroderma	0.0013	0.0067	CbGpPWpGaD
Boceprevir—CTSV—Extracellular matrix organization—HSPG2—systemic scleroderma	0.0013	0.00667	CbGpPWpGaD
Boceprevir—CTSL—Extracellular matrix organization—HSPG2—systemic scleroderma	0.0013	0.00667	CbGpPWpGaD
Boceprevir—CTSV—Extracellular matrix organization—COL1A2—systemic scleroderma	0.0013	0.00667	CbGpPWpGaD
Boceprevir—CTSL—Extracellular matrix organization—COL1A2—systemic scleroderma	0.0013	0.00667	CbGpPWpGaD
Boceprevir—CTSS—Extracellular matrix organization—FBN1—systemic scleroderma	0.00127	0.0065	CbGpPWpGaD
Boceprevir—CTSL—Assembly of collagen fibrils and other multimeric structures—MMP9—systemic scleroderma	0.00126	0.00647	CbGpPWpGaD
Boceprevir—CTSV—Assembly of collagen fibrils and other multimeric structures—MMP9—systemic scleroderma	0.00126	0.00647	CbGpPWpGaD
Boceprevir—CMA1—Extracellular matrix organization—HSPG2—systemic scleroderma	0.00121	0.0062	CbGpPWpGaD
Boceprevir—CMA1—Extracellular matrix organization—COL1A2—systemic scleroderma	0.00121	0.0062	CbGpPWpGaD
Boceprevir—ABCB1—blood vessel—systemic scleroderma	0.0012	0.00787	CbGeAlD
Boceprevir—CTSL—Extracellular matrix organization—ITGAM—systemic scleroderma	0.00118	0.00605	CbGpPWpGaD
Boceprevir—CTSV—Extracellular matrix organization—ITGAM—systemic scleroderma	0.00118	0.00605	CbGpPWpGaD
Boceprevir—CTSK—Degradation of the extracellular matrix—MMP1—systemic scleroderma	0.00117	0.006	CbGpPWpGaD
Boceprevir—CTSL—Betamethasone—Mometasone—systemic scleroderma	0.00115	0.197	CbGdCrCtD
Boceprevir—CTSL—Dexamethasone—Mometasone—systemic scleroderma	0.00115	0.197	CbGdCrCtD
Boceprevir—CMA1—Extracellular matrix organization—ITGAM—systemic scleroderma	0.0011	0.00563	CbGpPWpGaD
Boceprevir—CTSV—Degradation of the extracellular matrix—MMP2—systemic scleroderma	0.00109	0.0056	CbGpPWpGaD
Boceprevir—CTSL—Degradation of the extracellular matrix—MMP2—systemic scleroderma	0.00109	0.0056	CbGpPWpGaD
Boceprevir—CTSK—Extracellular matrix organization—HSPG2—systemic scleroderma	0.00108	0.00552	CbGpPWpGaD
Boceprevir—CTSK—Extracellular matrix organization—COL1A2—systemic scleroderma	0.00108	0.00552	CbGpPWpGaD
Boceprevir—CTSS—MHC class II antigen presentation—HLA-DQB1—systemic scleroderma	0.00107	0.00552	CbGpPWpGaD
Boceprevir—CTSV—Endochondral Ossification—MMP9—systemic scleroderma	0.00107	0.00548	CbGpPWpGaD
Boceprevir—CMA1—Degradation of the extracellular matrix—MMP2—systemic scleroderma	0.00101	0.00521	CbGpPWpGaD
Boceprevir—CTSK—Extracellular matrix organization—ITGAM—systemic scleroderma	0.000976	0.00502	CbGpPWpGaD
Boceprevir—CTSS—Degradation of the extracellular matrix—MMP1—systemic scleroderma	0.000961	0.00494	CbGpPWpGaD
Boceprevir—CTSK—Degradation of the extracellular matrix—MMP2—systemic scleroderma	0.000903	0.00464	CbGpPWpGaD
Boceprevir—CTSS—Extracellular matrix organization—HSPG2—systemic scleroderma	0.000885	0.00455	CbGpPWpGaD
Boceprevir—CTSS—Extracellular matrix organization—COL1A2—systemic scleroderma	0.000885	0.00455	CbGpPWpGaD
Boceprevir—CTSV—Endochondral Ossification—TGFB1—systemic scleroderma	0.000879	0.00452	CbGpPWpGaD
Boceprevir—CTSS—Assembly of collagen fibrils and other multimeric structures—MMP9—systemic scleroderma	0.00086	0.00442	CbGpPWpGaD
Boceprevir—CTSL—Collagen formation—MMP9—systemic scleroderma	0.000858	0.00441	CbGpPWpGaD
Boceprevir—CTSV—Collagen formation—MMP9—systemic scleroderma	0.000858	0.00441	CbGpPWpGaD
Boceprevir—CYP3A5—digestive system—systemic scleroderma	0.000836	0.00549	CbGeAlD
Boceprevir—CTSL—Degradation of the extracellular matrix—MMP9—systemic scleroderma	0.000819	0.00421	CbGpPWpGaD
Boceprevir—CTSV—Degradation of the extracellular matrix—MMP9—systemic scleroderma	0.000819	0.00421	CbGpPWpGaD
Boceprevir—CTSS—Extracellular matrix organization—ITGAM—systemic scleroderma	0.000804	0.00413	CbGpPWpGaD
Boceprevir—CTSL—Primary Focal Segmental Glomerulosclerosis FSGS—TGFB1—systemic scleroderma	0.0008	0.00411	CbGpPWpGaD
Boceprevir—CMA1—Degradation of the extracellular matrix—MMP9—systemic scleroderma	0.000762	0.00391	CbGpPWpGaD
Boceprevir—CTSS—Degradation of the extracellular matrix—MMP2—systemic scleroderma	0.000744	0.00382	CbGpPWpGaD
Boceprevir—CYP3A5—lung—systemic scleroderma	0.000698	0.00458	CbGeAlD
Boceprevir—CTSK—Degradation of the extracellular matrix—MMP9—systemic scleroderma	0.000679	0.00349	CbGpPWpGaD
Boceprevir—CTSV—Adaptive Immune System—CSK—systemic scleroderma	0.000644	0.00331	CbGpPWpGaD
Boceprevir—CTSL—Adaptive Immune System—CSK—systemic scleroderma	0.000644	0.00331	CbGpPWpGaD
Boceprevir—CTSL—Innate Immune System—ITGAM—systemic scleroderma	0.00063	0.00324	CbGpPWpGaD
Boceprevir—CTSV—Innate Immune System—ITGAM—systemic scleroderma	0.00063	0.00324	CbGpPWpGaD
Boceprevir—CTSV—Innate Immune System—CD247—systemic scleroderma	0.00063	0.00324	CbGpPWpGaD
Boceprevir—CTSL—Innate Immune System—CD247—systemic scleroderma	0.00063	0.00324	CbGpPWpGaD
Boceprevir—CYP3A4—digestive system—systemic scleroderma	0.000627	0.00412	CbGeAlD
Boceprevir—CTSL—Dexamethasone—Prednisone—systemic scleroderma	0.000627	0.108	CbGdCrCtD
Boceprevir—CTSL—Betamethasone—Prednisone—systemic scleroderma	0.000627	0.108	CbGdCrCtD
Boceprevir—CTSL—Adaptive Immune System—CD247—systemic scleroderma	0.000605	0.00311	CbGpPWpGaD
Boceprevir—CTSV—Adaptive Immune System—CD247—systemic scleroderma	0.000605	0.00311	CbGpPWpGaD
Boceprevir—CTSL—Extracellular matrix organization—MMP1—systemic scleroderma	0.00059	0.00303	CbGpPWpGaD
Boceprevir—CTSV—Extracellular matrix organization—MMP1—systemic scleroderma	0.00059	0.00303	CbGpPWpGaD
Boceprevir—CTSV—Innate Immune System—TNFAIP3—systemic scleroderma	0.00059	0.00303	CbGpPWpGaD
Boceprevir—CTSL—Innate Immune System—TNFAIP3—systemic scleroderma	0.00059	0.00303	CbGpPWpGaD
Boceprevir—CTSS—Collagen formation—MMP9—systemic scleroderma	0.000586	0.00301	CbGpPWpGaD
Boceprevir—CTSV—Adaptive Immune System—BLK—systemic scleroderma	0.00056	0.00288	CbGpPWpGaD
Boceprevir—CTSL—Adaptive Immune System—BLK—systemic scleroderma	0.00056	0.00288	CbGpPWpGaD
Boceprevir—CTSS—Degradation of the extracellular matrix—MMP9—systemic scleroderma	0.000559	0.00287	CbGpPWpGaD
Boceprevir—CMA1—Extracellular matrix organization—MMP1—systemic scleroderma	0.000549	0.00282	CbGpPWpGaD
Boceprevir—CTSK—Adaptive Immune System—CSK—systemic scleroderma	0.000533	0.00274	CbGpPWpGaD
Boceprevir—CMA1—Signaling by SCF-KIT—MMP9—systemic scleroderma	0.000527	0.00271	CbGpPWpGaD
Boceprevir—CTSK—Innate Immune System—ITGAM—systemic scleroderma	0.000522	0.00268	CbGpPWpGaD
Boceprevir—CTSK—Innate Immune System—CD247—systemic scleroderma	0.000522	0.00268	CbGpPWpGaD
Boceprevir—CTSK—Adaptive Immune System—CD247—systemic scleroderma	0.000501	0.00258	CbGpPWpGaD
Boceprevir—CTSK—Extracellular matrix organization—MMP1—systemic scleroderma	0.000489	0.00251	CbGpPWpGaD
Boceprevir—CTSK—Innate Immune System—TNFAIP3—systemic scleroderma	0.000489	0.00251	CbGpPWpGaD
Boceprevir—CTSK—Adaptive Immune System—BLK—systemic scleroderma	0.000464	0.00238	CbGpPWpGaD
Boceprevir—CTSV—Adaptive Immune System—CTLA4—systemic scleroderma	0.000459	0.00236	CbGpPWpGaD
Boceprevir—CTSL—Adaptive Immune System—CTLA4—systemic scleroderma	0.000459	0.00236	CbGpPWpGaD
Boceprevir—CTSV—Extracellular matrix organization—MMP2—systemic scleroderma	0.000457	0.00235	CbGpPWpGaD
Boceprevir—CTSL—Extracellular matrix organization—MMP2—systemic scleroderma	0.000457	0.00235	CbGpPWpGaD
Boceprevir—ABCB1—digestive system—systemic scleroderma	0.000444	0.00292	CbGeAlD
Boceprevir—CTSS—Adaptive Immune System—CSK—systemic scleroderma	0.000439	0.00226	CbGpPWpGaD
Boceprevir—CTSS—Innate Immune System—ITGAM—systemic scleroderma	0.00043	0.00221	CbGpPWpGaD
Boceprevir—CTSS—Innate Immune System—CD247—systemic scleroderma	0.00043	0.00221	CbGpPWpGaD
Boceprevir—CMA1—Extracellular matrix organization—MMP2—systemic scleroderma	0.000425	0.00218	CbGpPWpGaD
Boceprevir—CTSS—Adaptive Immune System—CD247—systemic scleroderma	0.000413	0.00212	CbGpPWpGaD
Boceprevir—CTSS—Extracellular matrix organization—MMP1—systemic scleroderma	0.000403	0.00207	CbGpPWpGaD
Boceprevir—CTSS—Innate Immune System—TNFAIP3—systemic scleroderma	0.000403	0.00207	CbGpPWpGaD
Boceprevir—CMA1—Metabolism of proteins—ACE—systemic scleroderma	0.0004	0.00205	CbGpPWpGaD
Boceprevir—CTSL—Immune System—CSK—systemic scleroderma	0.00039	0.00201	CbGpPWpGaD
Boceprevir—CTSV—Immune System—CSK—systemic scleroderma	0.00039	0.00201	CbGpPWpGaD
Boceprevir—CTSV—Immune System—IRF5—systemic scleroderma	0.000384	0.00197	CbGpPWpGaD
Boceprevir—CTSL—Immune System—IRF5—systemic scleroderma	0.000384	0.00197	CbGpPWpGaD
Boceprevir—CTSS—Adaptive Immune System—BLK—systemic scleroderma	0.000382	0.00196	CbGpPWpGaD
Boceprevir—CTSK—Adaptive Immune System—CTLA4—systemic scleroderma	0.00038	0.00195	CbGpPWpGaD
Boceprevir—CTSK—Extracellular matrix organization—MMP2—systemic scleroderma	0.000379	0.00195	CbGpPWpGaD
Boceprevir—CTSL—Adaptive Immune System—HLA-DQB1—systemic scleroderma	0.000378	0.00194	CbGpPWpGaD
Boceprevir—CTSV—Adaptive Immune System—HLA-DQB1—systemic scleroderma	0.000378	0.00194	CbGpPWpGaD
Boceprevir—ABCB1—lung—systemic scleroderma	0.000371	0.00243	CbGeAlD
Boceprevir—CTSL—Immune System—IRF8—systemic scleroderma	0.000367	0.00189	CbGpPWpGaD
Boceprevir—CTSV—Immune System—IRF8—systemic scleroderma	0.000367	0.00189	CbGpPWpGaD
Boceprevir—CTSL—Immune System—ITGAM—systemic scleroderma	0.000367	0.00189	CbGpPWpGaD
Boceprevir—CTSV—Immune System—ITGAM—systemic scleroderma	0.000367	0.00189	CbGpPWpGaD
Boceprevir—CTSL—Immune System—CD247—systemic scleroderma	0.000367	0.00189	CbGpPWpGaD
Boceprevir—CTSV—Immune System—CD247—systemic scleroderma	0.000367	0.00189	CbGpPWpGaD
Boceprevir—CTSV—Adaptive Immune System—CD40LG—systemic scleroderma	0.000357	0.00183	CbGpPWpGaD
Boceprevir—CTSL—Adaptive Immune System—CD40LG—systemic scleroderma	0.000357	0.00183	CbGpPWpGaD
Boceprevir—CTSV—Immune System—TNFAIP3—systemic scleroderma	0.000344	0.00177	CbGpPWpGaD
Boceprevir—CTSL—Immune System—TNFAIP3—systemic scleroderma	0.000344	0.00177	CbGpPWpGaD
Boceprevir—CTSV—Extracellular matrix organization—MMP9—systemic scleroderma	0.000343	0.00176	CbGpPWpGaD
Boceprevir—CTSL—Extracellular matrix organization—MMP9—systemic scleroderma	0.000343	0.00176	CbGpPWpGaD
Boceprevir—CTSV—Immune System—BLK—systemic scleroderma	0.00034	0.00175	CbGpPWpGaD
Boceprevir—CTSL—Immune System—BLK—systemic scleroderma	0.00034	0.00175	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—SMAD7—systemic scleroderma	0.000333	0.00171	CbGpPWpGaD
Boceprevir—ABCB1—Allograft Rejection—IL13—systemic scleroderma	0.000328	0.00168	CbGpPWpGaD
Boceprevir—CTSK—Immune System—CSK—systemic scleroderma	0.000324	0.00166	CbGpPWpGaD
Boceprevir—CMA1—Extracellular matrix organization—MMP9—systemic scleroderma	0.000319	0.00164	CbGpPWpGaD
Boceprevir—CTSK—Immune System—IRF5—systemic scleroderma	0.000318	0.00164	CbGpPWpGaD
Boceprevir—CTSS—Adaptive Immune System—CTLA4—systemic scleroderma	0.000313	0.00161	CbGpPWpGaD
Boceprevir—CTSK—Adaptive Immune System—HLA-DQB1—systemic scleroderma	0.000313	0.00161	CbGpPWpGaD
Boceprevir—CTSS—Extracellular matrix organization—MMP2—systemic scleroderma	0.000312	0.0016	CbGpPWpGaD
Boceprevir—CTSK—Immune System—IRF8—systemic scleroderma	0.000304	0.00156	CbGpPWpGaD
Boceprevir—CTSK—Immune System—ITGAM—systemic scleroderma	0.000304	0.00156	CbGpPWpGaD
Boceprevir—CTSK—Immune System—CD247—systemic scleroderma	0.000304	0.00156	CbGpPWpGaD
Boceprevir—CTSK—Adaptive Immune System—CD40LG—systemic scleroderma	0.000296	0.00152	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.000291	0.00149	CbGpPWpGaD
Boceprevir—CTSK—Immune System—TNFAIP3—systemic scleroderma	0.000285	0.00146	CbGpPWpGaD
Boceprevir—CTSK—Extracellular matrix organization—MMP9—systemic scleroderma	0.000285	0.00146	CbGpPWpGaD
Boceprevir—CTSV—Extracellular matrix organization—TGFB1—systemic scleroderma	0.000283	0.00145	CbGpPWpGaD
Boceprevir—CTSL—Extracellular matrix organization—TGFB1—systemic scleroderma	0.000283	0.00145	CbGpPWpGaD
Boceprevir—CTSK—Immune System—BLK—systemic scleroderma	0.000281	0.00145	CbGpPWpGaD
Boceprevir—CTSV—Immune System—CTLA4—systemic scleroderma	0.000278	0.00143	CbGpPWpGaD
Boceprevir—CTSL—Immune System—CTLA4—systemic scleroderma	0.000278	0.00143	CbGpPWpGaD
Boceprevir—CTSS—Immune System—CSK—systemic scleroderma	0.000266	0.00137	CbGpPWpGaD
Boceprevir—ABCB1—Allograft Rejection—CTLA4—systemic scleroderma	0.000264	0.00135	CbGpPWpGaD
Boceprevir—CMA1—Extracellular matrix organization—TGFB1—systemic scleroderma	0.000263	0.00135	CbGpPWpGaD
Boceprevir—CTSS—Immune System—IRF5—systemic scleroderma	0.000262	0.00135	CbGpPWpGaD
Boceprevir—CTSS—Adaptive Immune System—HLA-DQB1—systemic scleroderma	0.000258	0.00132	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—RHOB—systemic scleroderma	0.000258	0.00132	CbGpPWpGaD
Boceprevir—CMA1—Metabolism of proteins—MMP1—systemic scleroderma	0.000257	0.00132	CbGpPWpGaD
Boceprevir—CTSS—Immune System—IRF8—systemic scleroderma	0.00025	0.00129	CbGpPWpGaD
Boceprevir—CTSS—Immune System—ITGAM—systemic scleroderma	0.00025	0.00129	CbGpPWpGaD
Boceprevir—CTSS—Immune System—CD247—systemic scleroderma	0.00025	0.00129	CbGpPWpGaD
Boceprevir—CTSS—Adaptive Immune System—CD40LG—systemic scleroderma	0.000243	0.00125	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—HSPG2—systemic scleroderma	0.000243	0.00125	CbGpPWpGaD
Boceprevir—ABCB1—HIF-1-alpha transcription factor network—EDN1—systemic scleroderma	0.000239	0.00123	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—CSK—systemic scleroderma	0.000235	0.00121	CbGpPWpGaD
Boceprevir—CTSS—Immune System—TNFAIP3—systemic scleroderma	0.000235	0.00121	CbGpPWpGaD
Boceprevir—CTSK—Extracellular matrix organization—TGFB1—systemic scleroderma	0.000234	0.00121	CbGpPWpGaD
Boceprevir—CTSS—Extracellular matrix organization—MMP9—systemic scleroderma	0.000234	0.0012	CbGpPWpGaD
Boceprevir—CTSS—Immune System—BLK—systemic scleroderma	0.000232	0.00119	CbGpPWpGaD
Boceprevir—CTSK—Immune System—CTLA4—systemic scleroderma	0.000231	0.00118	CbGpPWpGaD
Boceprevir—CTSL—Immune System—HLA-DQB1—systemic scleroderma	0.000229	0.00118	CbGpPWpGaD
Boceprevir—CTSV—Immune System—HLA-DQB1—systemic scleroderma	0.000229	0.00118	CbGpPWpGaD
Boceprevir—CTSV—Immune System—IL1A—systemic scleroderma	0.000218	0.00112	CbGpPWpGaD
Boceprevir—CTSL—Immune System—IL1A—systemic scleroderma	0.000218	0.00112	CbGpPWpGaD
Boceprevir—ABCB1—Allograft Rejection—HLA-DQB1—systemic scleroderma	0.000217	0.00112	CbGpPWpGaD
Boceprevir—CTSL—Immune System—CD40LG—systemic scleroderma	0.000216	0.00111	CbGpPWpGaD
Boceprevir—CTSV—Immune System—CD40LG—systemic scleroderma	0.000216	0.00111	CbGpPWpGaD
Boceprevir—CMA1—Metabolism of proteins—CCL2—systemic scleroderma	0.000209	0.00107	CbGpPWpGaD
Boceprevir—ABCB1—Allograft Rejection—IL1A—systemic scleroderma	0.000206	0.00106	CbGpPWpGaD
Boceprevir—ABCB1—Allograft Rejection—CD40LG—systemic scleroderma	0.000205	0.00105	CbGpPWpGaD
Boceprevir—CMA1—Metabolism of proteins—MMP2—systemic scleroderma	0.000199	0.00102	CbGpPWpGaD
Boceprevir—CTSS—Extracellular matrix organization—TGFB1—systemic scleroderma	0.000193	0.000992	CbGpPWpGaD
Boceprevir—CTSS—Immune System—CTLA4—systemic scleroderma	0.00019	0.000975	CbGpPWpGaD
Boceprevir—CTSK—Immune System—HLA-DQB1—systemic scleroderma	0.00019	0.000975	CbGpPWpGaD
Boceprevir—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000187	0.000523	CcSEcCtD
Boceprevir—Pain—Mycophenolic acid—systemic scleroderma	0.000186	0.000522	CcSEcCtD
Boceprevir—Constipation—Mycophenolic acid—systemic scleroderma	0.000186	0.000522	CcSEcCtD
Boceprevir—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000186	0.000521	CcSEcCtD
Boceprevir—Weight decreased—Prednisone—systemic scleroderma	0.000185	0.000519	CcSEcCtD
Boceprevir—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000185	0.000519	CcSEcCtD
Boceprevir—Hyperglycaemia—Prednisone—systemic scleroderma	0.000185	0.000518	CcSEcCtD
Boceprevir—Cough—Mycophenolate mofetil—systemic scleroderma	0.000184	0.000515	CcSEcCtD
Boceprevir—Hypotension—Lisinopril—systemic scleroderma	0.000183	0.000514	CcSEcCtD
Boceprevir—Dizziness—Captopril—systemic scleroderma	0.000183	0.000513	CcSEcCtD
Boceprevir—Depression—Prednisone—systemic scleroderma	0.000182	0.00051	CcSEcCtD
Boceprevir—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000182	0.000509	CcSEcCtD
Boceprevir—Urticaria—Leflunomide—systemic scleroderma	0.000181	0.000508	CcSEcCtD
Boceprevir—Abdominal pain—Leflunomide—systemic scleroderma	0.00018	0.000506	CcSEcCtD
Boceprevir—Body temperature increased—Leflunomide—systemic scleroderma	0.00018	0.000506	CcSEcCtD
Boceprevir—CTSK—Immune System—IL1A—systemic scleroderma	0.00018	0.000927	CbGpPWpGaD
Boceprevir—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000179	0.000503	CcSEcCtD
Boceprevir—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000179	0.000502	CcSEcCtD
Boceprevir—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000179	0.000502	CcSEcCtD
Boceprevir—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000179	0.000502	CcSEcCtD
Boceprevir—CTSK—Immune System—CD40LG—systemic scleroderma	0.000179	0.000921	CbGpPWpGaD
Boceprevir—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000179	0.000502	CcSEcCtD
Boceprevir—Breast disorder—Methotrexate—systemic scleroderma	0.000179	0.000502	CcSEcCtD
Boceprevir—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000179	0.000501	CcSEcCtD
Boceprevir—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000179	0.000501	CcSEcCtD
Boceprevir—Hypersensitivity—Azathioprine—systemic scleroderma	0.000178	0.000499	CcSEcCtD
Boceprevir—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000178	0.000499	CcSEcCtD
Boceprevir—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000178	0.000499	CcSEcCtD
Boceprevir—Insomnia—Lisinopril—systemic scleroderma	0.000177	0.000497	CcSEcCtD
Boceprevir—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000177	0.000496	CcSEcCtD
Boceprevir—Paraesthesia—Lisinopril—systemic scleroderma	0.000176	0.000494	CcSEcCtD
Boceprevir—Vomiting—Captopril—systemic scleroderma	0.000176	0.000493	CcSEcCtD
Boceprevir—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000175	0.000491	CcSEcCtD
Boceprevir—Dyspnoea—Lisinopril—systemic scleroderma	0.000175	0.00049	CcSEcCtD
Boceprevir—Rash—Captopril—systemic scleroderma	0.000175	0.000489	CcSEcCtD
Boceprevir—Dermatitis—Captopril—systemic scleroderma	0.000174	0.000489	CcSEcCtD
Boceprevir—Headache—Captopril—systemic scleroderma	0.000174	0.000486	CcSEcCtD
Boceprevir—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000173	0.000486	CcSEcCtD
Boceprevir—Dyspepsia—Lisinopril—systemic scleroderma	0.000173	0.000484	CcSEcCtD
Boceprevir—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000172	0.000482	CcSEcCtD
Boceprevir—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000172	0.000482	CcSEcCtD
Boceprevir—Infection—Mycophenolate mofetil—systemic scleroderma	0.000171	0.000478	CcSEcCtD
Boceprevir—Decreased appetite—Lisinopril—systemic scleroderma	0.000171	0.000478	CcSEcCtD
Boceprevir—Eosinophilia—Methotrexate—systemic scleroderma	0.00017	0.000475	CcSEcCtD
Boceprevir—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000169	0.000474	CcSEcCtD
Boceprevir—Fatigue—Lisinopril—systemic scleroderma	0.000169	0.000474	CcSEcCtD
Boceprevir—Shock—Mycophenolate mofetil—systemic scleroderma	0.000169	0.000474	CcSEcCtD
Boceprevir—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000169	0.000472	CcSEcCtD
Boceprevir—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000168	0.000471	CcSEcCtD
Boceprevir—Hypersensitivity—Leflunomide—systemic scleroderma	0.000168	0.000471	CcSEcCtD
Boceprevir—Pancreatitis—Methotrexate—systemic scleroderma	0.000168	0.00047	CcSEcCtD
Boceprevir—Pain—Lisinopril—systemic scleroderma	0.000168	0.00047	CcSEcCtD
Boceprevir—Constipation—Lisinopril—systemic scleroderma	0.000168	0.00047	CcSEcCtD
Boceprevir—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000168	0.00047	CcSEcCtD
Boceprevir—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000167	0.000468	CcSEcCtD
Boceprevir—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000166	0.000466	CcSEcCtD
Boceprevir—Diarrhoea—Azathioprine—systemic scleroderma	0.000165	0.000463	CcSEcCtD
Boceprevir—Nausea—Captopril—systemic scleroderma	0.000165	0.000461	CcSEcCtD
Boceprevir—Abdominal discomfort—Methotrexate—systemic scleroderma	0.000164	0.00046	CcSEcCtD
Boceprevir—Asthenia—Leflunomide—systemic scleroderma	0.000164	0.000459	CcSEcCtD
Boceprevir—Pancytopenia—Methotrexate—systemic scleroderma	0.000163	0.000456	CcSEcCtD
Boceprevir—Feeling abnormal—Lisinopril—systemic scleroderma	0.000162	0.000453	CcSEcCtD
Boceprevir—Pruritus—Leflunomide—systemic scleroderma	0.000162	0.000453	CcSEcCtD
Boceprevir—Connective tissue disorder—Prednisone—systemic scleroderma	0.000161	0.000451	CcSEcCtD
Boceprevir—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000161	0.00045	CcSEcCtD
Boceprevir—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.00016	0.000449	CcSEcCtD
Boceprevir—Neutropenia—Methotrexate—systemic scleroderma	0.00016	0.000449	CcSEcCtD
Boceprevir—Dysuria—Methotrexate—systemic scleroderma	0.00016	0.000449	CcSEcCtD
Boceprevir—Dizziness—Azathioprine—systemic scleroderma	0.00016	0.000448	CcSEcCtD
Boceprevir—Erectile dysfunction—Methotrexate—systemic scleroderma	0.000158	0.000442	CcSEcCtD
Boceprevir—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000157	0.000439	CcSEcCtD
Boceprevir—CTSS—Immune System—HLA-DQB1—systemic scleroderma	0.000156	0.000803	CbGpPWpGaD
Boceprevir—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.000156	0.000438	CcSEcCtD
Boceprevir—Asthenia—Mycophenolic acid—systemic scleroderma	0.000156	0.000438	CcSEcCtD
Boceprevir—Diarrhoea—Leflunomide—systemic scleroderma	0.000156	0.000438	CcSEcCtD
Boceprevir—Urticaria—Lisinopril—systemic scleroderma	0.000156	0.000437	CcSEcCtD
Boceprevir—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000155	0.000436	CcSEcCtD
Boceprevir—Body temperature increased—Lisinopril—systemic scleroderma	0.000155	0.000434	CcSEcCtD
Boceprevir—Abdominal pain—Lisinopril—systemic scleroderma	0.000155	0.000434	CcSEcCtD
Boceprevir—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000154	0.000432	CcSEcCtD
Boceprevir—Pruritus—Mycophenolic acid—systemic scleroderma	0.000154	0.000432	CcSEcCtD
Boceprevir—Vomiting—Azathioprine—systemic scleroderma	0.000154	0.000431	CcSEcCtD
Boceprevir—Pneumonia—Methotrexate—systemic scleroderma	0.000154	0.00043	CcSEcCtD
Boceprevir—Eye disorder—Prednisone—systemic scleroderma	0.000153	0.000429	CcSEcCtD
Boceprevir—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000153	0.000429	CcSEcCtD
Boceprevir—Infestation NOS—Methotrexate—systemic scleroderma	0.000153	0.000428	CcSEcCtD
Boceprevir—Infestation—Methotrexate—systemic scleroderma	0.000153	0.000428	CcSEcCtD
Boceprevir—Rash—Azathioprine—systemic scleroderma	0.000152	0.000427	CcSEcCtD
Boceprevir—Dermatitis—Azathioprine—systemic scleroderma	0.000152	0.000427	CcSEcCtD
Boceprevir—Depression—Methotrexate—systemic scleroderma	0.000152	0.000426	CcSEcCtD
Boceprevir—Flushing—Prednisone—systemic scleroderma	0.000152	0.000426	CcSEcCtD
Boceprevir—Headache—Azathioprine—systemic scleroderma	0.000151	0.000424	CcSEcCtD
Boceprevir—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.000151	0.000424	CcSEcCtD
Boceprevir—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000151	0.000424	CcSEcCtD
Boceprevir—Dizziness—Leflunomide—systemic scleroderma	0.000151	0.000423	CcSEcCtD
Boceprevir—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000149	0.000419	CcSEcCtD
Boceprevir—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000149	0.000417	CcSEcCtD
Boceprevir—Stomatitis—Methotrexate—systemic scleroderma	0.000149	0.000417	CcSEcCtD
Boceprevir—Angiopathy—Prednisone—systemic scleroderma	0.000149	0.000417	CcSEcCtD
Boceprevir—CTSS—Immune System—IL1A—systemic scleroderma	0.000148	0.000763	CbGpPWpGaD
Boceprevir—Conjunctivitis—Methotrexate—systemic scleroderma	0.000148	0.000416	CcSEcCtD
Boceprevir—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000148	0.000416	CcSEcCtD
Boceprevir—Immune system disorder—Prednisone—systemic scleroderma	0.000148	0.000415	CcSEcCtD
Boceprevir—CTSS—Immune System—CD40LG—systemic scleroderma	0.000148	0.000759	CbGpPWpGaD
Boceprevir—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000147	0.000412	CcSEcCtD
Boceprevir—Pain—Mycophenolate mofetil—systemic scleroderma	0.000147	0.000412	CcSEcCtD
Boceprevir—Arrhythmia—Prednisone—systemic scleroderma	0.000146	0.00041	CcSEcCtD
Boceprevir—Vomiting—Leflunomide—systemic scleroderma	0.000145	0.000407	CcSEcCtD
Boceprevir—Alopecia—Prednisone—systemic scleroderma	0.000145	0.000406	CcSEcCtD
Boceprevir—Hypersensitivity—Lisinopril—systemic scleroderma	0.000145	0.000405	CcSEcCtD
Boceprevir—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000144	0.000405	CcSEcCtD
Boceprevir—Dizziness—Mycophenolic acid—systemic scleroderma	0.000144	0.000403	CcSEcCtD
Boceprevir—Epistaxis—Methotrexate—systemic scleroderma	0.000144	0.000403	CcSEcCtD
Boceprevir—Rash—Leflunomide—systemic scleroderma	0.000144	0.000403	CcSEcCtD
Boceprevir—Dermatitis—Leflunomide—systemic scleroderma	0.000144	0.000403	CcSEcCtD
Boceprevir—Mental disorder—Prednisone—systemic scleroderma	0.000144	0.000403	CcSEcCtD
Boceprevir—Nausea—Azathioprine—systemic scleroderma	0.000144	0.000402	CcSEcCtD
Boceprevir—Headache—Leflunomide—systemic scleroderma	0.000143	0.000401	CcSEcCtD
Boceprevir—Erythema—Prednisone—systemic scleroderma	0.000143	0.0004	CcSEcCtD
Boceprevir—Malnutrition—Prednisone—systemic scleroderma	0.000143	0.0004	CcSEcCtD
Boceprevir—Agranulocytosis—Methotrexate—systemic scleroderma	0.000142	0.000399	CcSEcCtD
Boceprevir—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000142	0.000397	CcSEcCtD
Boceprevir—Asthenia—Lisinopril—systemic scleroderma	0.000141	0.000394	CcSEcCtD
Boceprevir—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000141	0.000394	CcSEcCtD
Boceprevir—Pruritus—Lisinopril—systemic scleroderma	0.000139	0.000389	CcSEcCtD
Boceprevir—Vomiting—Mycophenolic acid—systemic scleroderma	0.000138	0.000388	CcSEcCtD
Boceprevir—Rash—Mycophenolic acid—systemic scleroderma	0.000137	0.000385	CcSEcCtD
Boceprevir—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000137	0.000384	CcSEcCtD
Boceprevir—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000137	0.000383	CcSEcCtD
Boceprevir—Headache—Mycophenolic acid—systemic scleroderma	0.000136	0.000382	CcSEcCtD
Boceprevir—Pharyngitis—Methotrexate—systemic scleroderma	0.000136	0.000381	CcSEcCtD
Boceprevir—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000136	0.000381	CcSEcCtD
Boceprevir—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000136	0.000381	CcSEcCtD
Boceprevir—Nausea—Leflunomide—systemic scleroderma	0.000136	0.00038	CcSEcCtD
Boceprevir—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000135	0.000379	CcSEcCtD
Boceprevir—Vision blurred—Prednisone—systemic scleroderma	0.000135	0.000377	CcSEcCtD
Boceprevir—Urethral disorder—Methotrexate—systemic scleroderma	0.000134	0.000376	CcSEcCtD
Boceprevir—Diarrhoea—Lisinopril—systemic scleroderma	0.000134	0.000376	CcSEcCtD
Boceprevir—Ill-defined disorder—Prednisone—systemic scleroderma	0.000132	0.000371	CcSEcCtD
Boceprevir—Visual impairment—Methotrexate—systemic scleroderma	0.000132	0.00037	CcSEcCtD
Boceprevir—Anaemia—Prednisone—systemic scleroderma	0.000132	0.00037	CcSEcCtD
Boceprevir—CMA1—Signaling Pathways—EDN1—systemic scleroderma	0.000132	0.000676	CbGpPWpGaD
Boceprevir—Agitation—Prednisone—systemic scleroderma	0.000131	0.000368	CcSEcCtD
Boceprevir—Angioedema—Prednisone—systemic scleroderma	0.00013	0.000365	CcSEcCtD
Boceprevir—Dizziness—Lisinopril—systemic scleroderma	0.00013	0.000363	CcSEcCtD
Boceprevir—Erythema multiforme—Methotrexate—systemic scleroderma	0.00013	0.000363	CcSEcCtD
Boceprevir—Nausea—Mycophenolic acid—systemic scleroderma	0.000129	0.000362	CcSEcCtD
Boceprevir—Malaise—Prednisone—systemic scleroderma	0.000129	0.000361	CcSEcCtD
Boceprevir—Vertigo—Prednisone—systemic scleroderma	0.000128	0.000359	CcSEcCtD
Boceprevir—Eye disorder—Methotrexate—systemic scleroderma	0.000128	0.000359	CcSEcCtD
Boceprevir—Syncope—Prednisone—systemic scleroderma	0.000128	0.000359	CcSEcCtD
Boceprevir—Tinnitus—Methotrexate—systemic scleroderma	0.000128	0.000358	CcSEcCtD
Boceprevir—Cardiac disorder—Methotrexate—systemic scleroderma	0.000127	0.000356	CcSEcCtD
Boceprevir—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000127	0.000355	CcSEcCtD
Boceprevir—Loss of consciousness—Prednisone—systemic scleroderma	0.000125	0.000352	CcSEcCtD
Boceprevir—Vomiting—Lisinopril—systemic scleroderma	0.000125	0.000349	CcSEcCtD
Boceprevir—Angiopathy—Methotrexate—systemic scleroderma	0.000124	0.000348	CcSEcCtD
Boceprevir—Immune system disorder—Methotrexate—systemic scleroderma	0.000124	0.000347	CcSEcCtD
Boceprevir—Rash—Lisinopril—systemic scleroderma	0.000124	0.000347	CcSEcCtD
Boceprevir—Dermatitis—Lisinopril—systemic scleroderma	0.000124	0.000346	CcSEcCtD
Boceprevir—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000124	0.000346	CcSEcCtD
Boceprevir—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000123	0.000345	CcSEcCtD
Boceprevir—Hypertension—Prednisone—systemic scleroderma	0.000123	0.000345	CcSEcCtD
Boceprevir—Chills—Methotrexate—systemic scleroderma	0.000123	0.000345	CcSEcCtD
Boceprevir—Headache—Lisinopril—systemic scleroderma	0.000123	0.000344	CcSEcCtD
Boceprevir—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000122	0.000341	CcSEcCtD
Boceprevir—Myalgia—Prednisone—systemic scleroderma	0.000122	0.000341	CcSEcCtD
Boceprevir—Arthralgia—Prednisone—systemic scleroderma	0.000122	0.000341	CcSEcCtD
Boceprevir—Anxiety—Prednisone—systemic scleroderma	0.000121	0.000339	CcSEcCtD
Boceprevir—Alopecia—Methotrexate—systemic scleroderma	0.000121	0.000339	CcSEcCtD
Boceprevir—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000121	0.000338	CcSEcCtD
Boceprevir—Discomfort—Prednisone—systemic scleroderma	0.00012	0.000336	CcSEcCtD
Boceprevir—Mental disorder—Methotrexate—systemic scleroderma	0.00012	0.000336	CcSEcCtD
Boceprevir—Malnutrition—Methotrexate—systemic scleroderma	0.000119	0.000334	CcSEcCtD
Boceprevir—Erythema—Methotrexate—systemic scleroderma	0.000119	0.000334	CcSEcCtD
Boceprevir—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000118	0.000329	CcSEcCtD
Boceprevir—Dysgeusia—Methotrexate—systemic scleroderma	0.000117	0.000327	CcSEcCtD
Boceprevir—Nausea—Lisinopril—systemic scleroderma	0.000117	0.000326	CcSEcCtD
Boceprevir—Infection—Prednisone—systemic scleroderma	0.000116	0.000324	CcSEcCtD
Boceprevir—Back pain—Methotrexate—systemic scleroderma	0.000115	0.000323	CcSEcCtD
Boceprevir—Shock—Prednisone—systemic scleroderma	0.000115	0.000321	CcSEcCtD
Boceprevir—Nervous system disorder—Prednisone—systemic scleroderma	0.000114	0.00032	CcSEcCtD
Boceprevir—Tachycardia—Prednisone—systemic scleroderma	0.000114	0.000319	CcSEcCtD
Boceprevir—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000114	0.000318	CcSEcCtD
Boceprevir—CTSV—Immune System—IL1B—systemic scleroderma	0.000113	0.000583	CbGpPWpGaD
Boceprevir—CTSL—Immune System—IL1B—systemic scleroderma	0.000113	0.000583	CbGpPWpGaD
Boceprevir—Skin disorder—Prednisone—systemic scleroderma	0.000113	0.000317	CcSEcCtD
Boceprevir—Hyperhidrosis—Prednisone—systemic scleroderma	0.000113	0.000316	CcSEcCtD
Boceprevir—Vision blurred—Methotrexate—systemic scleroderma	0.000112	0.000315	CcSEcCtD
Boceprevir—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000111	0.00031	CcSEcCtD
Boceprevir—Anaemia—Methotrexate—systemic scleroderma	0.00011	0.000309	CcSEcCtD
Boceprevir—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000109	0.000306	CcSEcCtD
Boceprevir—Rash—Mycophenolate mofetil—systemic scleroderma	0.000108	0.000304	CcSEcCtD
Boceprevir—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000108	0.000303	CcSEcCtD
Boceprevir—Headache—Mycophenolate mofetil—systemic scleroderma	0.000108	0.000302	CcSEcCtD
Boceprevir—Malaise—Methotrexate—systemic scleroderma	0.000108	0.000301	CcSEcCtD
Boceprevir—ABCB1—Allograft Rejection—IL1B—systemic scleroderma	0.000108	0.000553	CbGpPWpGaD
Boceprevir—Vertigo—Methotrexate—systemic scleroderma	0.000107	0.0003	CcSEcCtD
Boceprevir—Leukopenia—Methotrexate—systemic scleroderma	0.000107	0.000299	CcSEcCtD
Boceprevir—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000106	0.000297	CcSEcCtD
Boceprevir—Insomnia—Prednisone—systemic scleroderma	0.000105	0.000295	CcSEcCtD
Boceprevir—Paraesthesia—Prednisone—systemic scleroderma	0.000105	0.000293	CcSEcCtD
Boceprevir—Cough—Methotrexate—systemic scleroderma	0.000104	0.000292	CcSEcCtD
Boceprevir—Dyspepsia—Prednisone—systemic scleroderma	0.000103	0.000287	CcSEcCtD
Boceprevir—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000102	0.000286	CcSEcCtD
Boceprevir—Arthralgia—Methotrexate—systemic scleroderma	0.000102	0.000285	CcSEcCtD
Boceprevir—Chest pain—Methotrexate—systemic scleroderma	0.000102	0.000285	CcSEcCtD
Boceprevir—Myalgia—Methotrexate—systemic scleroderma	0.000102	0.000285	CcSEcCtD
Boceprevir—Decreased appetite—Prednisone—systemic scleroderma	0.000101	0.000284	CcSEcCtD
Boceprevir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000101	0.000283	CcSEcCtD
Boceprevir—Fatigue—Prednisone—systemic scleroderma	0.0001	0.000281	CcSEcCtD
Boceprevir—Discomfort—Methotrexate—systemic scleroderma	0.0001	0.000281	CcSEcCtD
Boceprevir—Constipation—Prednisone—systemic scleroderma	9.96e-05	0.000279	CcSEcCtD
Boceprevir—Confusional state—Methotrexate—systemic scleroderma	9.82e-05	0.000275	CcSEcCtD
Boceprevir—Infection—Methotrexate—systemic scleroderma	9.67e-05	0.000271	CcSEcCtD
Boceprevir—Feeling abnormal—Prednisone—systemic scleroderma	9.6e-05	0.000269	CcSEcCtD
Boceprevir—Nervous system disorder—Methotrexate—systemic scleroderma	9.55e-05	0.000268	CcSEcCtD
Boceprevir—Thrombocytopenia—Methotrexate—systemic scleroderma	9.53e-05	0.000267	CcSEcCtD
Boceprevir—Gastrointestinal pain—Prednisone—systemic scleroderma	9.53e-05	0.000267	CcSEcCtD
Boceprevir—Skin disorder—Methotrexate—systemic scleroderma	9.46e-05	0.000265	CcSEcCtD
Boceprevir—Hyperhidrosis—Methotrexate—systemic scleroderma	9.41e-05	0.000264	CcSEcCtD
Boceprevir—CTSK—Immune System—IL1B—systemic scleroderma	9.4e-05	0.000483	CbGpPWpGaD
Boceprevir—Urticaria—Prednisone—systemic scleroderma	9.26e-05	0.000259	CcSEcCtD
Boceprevir—Abdominal pain—Prednisone—systemic scleroderma	9.21e-05	0.000258	CcSEcCtD
Boceprevir—Body temperature increased—Prednisone—systemic scleroderma	9.21e-05	0.000258	CcSEcCtD
Boceprevir—Hypotension—Methotrexate—systemic scleroderma	9.1e-05	0.000255	CcSEcCtD
Boceprevir—CMA1—Signaling Pathways—CCL2—systemic scleroderma	8.99e-05	0.000462	CbGpPWpGaD
Boceprevir—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	8.87e-05	0.000249	CcSEcCtD
Boceprevir—Insomnia—Methotrexate—systemic scleroderma	8.81e-05	0.000247	CcSEcCtD
Boceprevir—Paraesthesia—Methotrexate—systemic scleroderma	8.74e-05	0.000245	CcSEcCtD
Boceprevir—Dyspnoea—Methotrexate—systemic scleroderma	8.68e-05	0.000243	CcSEcCtD
Boceprevir—Hypersensitivity—Prednisone—systemic scleroderma	8.58e-05	0.00024	CcSEcCtD
Boceprevir—Dyspepsia—Methotrexate—systemic scleroderma	8.57e-05	0.00024	CcSEcCtD
Boceprevir—Decreased appetite—Methotrexate—systemic scleroderma	8.46e-05	0.000237	CcSEcCtD
Boceprevir—Gastrointestinal disorder—Methotrexate—systemic scleroderma	8.41e-05	0.000236	CcSEcCtD
Boceprevir—Fatigue—Methotrexate—systemic scleroderma	8.39e-05	0.000235	CcSEcCtD
Boceprevir—Asthenia—Prednisone—systemic scleroderma	8.36e-05	0.000234	CcSEcCtD
Boceprevir—ABCB1—Allograft Rejection—TGFB1—systemic scleroderma	8.36e-05	0.000429	CbGpPWpGaD
Boceprevir—Pain—Methotrexate—systemic scleroderma	8.33e-05	0.000233	CcSEcCtD
Boceprevir—Pruritus—Prednisone—systemic scleroderma	8.24e-05	0.000231	CcSEcCtD
Boceprevir—Feeling abnormal—Methotrexate—systemic scleroderma	8.02e-05	0.000225	CcSEcCtD
Boceprevir—CMA1—Signaling Pathways—NOS3—systemic scleroderma	8.02e-05	0.000412	CbGpPWpGaD
Boceprevir—Diarrhoea—Prednisone—systemic scleroderma	7.97e-05	0.000223	CcSEcCtD
Boceprevir—Gastrointestinal pain—Methotrexate—systemic scleroderma	7.96e-05	0.000223	CcSEcCtD
Boceprevir—CTSS—Immune System—IL1B—systemic scleroderma	7.74e-05	0.000398	CbGpPWpGaD
Boceprevir—Urticaria—Methotrexate—systemic scleroderma	7.73e-05	0.000217	CcSEcCtD
Boceprevir—Dizziness—Prednisone—systemic scleroderma	7.7e-05	0.000216	CcSEcCtD
Boceprevir—Body temperature increased—Methotrexate—systemic scleroderma	7.7e-05	0.000216	CcSEcCtD
Boceprevir—Abdominal pain—Methotrexate—systemic scleroderma	7.7e-05	0.000216	CcSEcCtD
Boceprevir—Vomiting—Prednisone—systemic scleroderma	7.41e-05	0.000208	CcSEcCtD
Boceprevir—Rash—Prednisone—systemic scleroderma	7.35e-05	0.000206	CcSEcCtD
Boceprevir—Dermatitis—Prednisone—systemic scleroderma	7.34e-05	0.000206	CcSEcCtD
Boceprevir—Headache—Prednisone—systemic scleroderma	7.3e-05	0.000204	CcSEcCtD
Boceprevir—Hypersensitivity—Methotrexate—systemic scleroderma	7.17e-05	0.000201	CcSEcCtD
Boceprevir—Asthenia—Methotrexate—systemic scleroderma	6.99e-05	0.000196	CcSEcCtD
Boceprevir—Nausea—Prednisone—systemic scleroderma	6.92e-05	0.000194	CcSEcCtD
Boceprevir—Pruritus—Methotrexate—systemic scleroderma	6.89e-05	0.000193	CcSEcCtD
Boceprevir—Diarrhoea—Methotrexate—systemic scleroderma	6.66e-05	0.000187	CcSEcCtD
Boceprevir—Dizziness—Methotrexate—systemic scleroderma	6.44e-05	0.00018	CcSEcCtD
Boceprevir—CMA1—Signaling Pathways—MMP9—systemic scleroderma	6.43e-05	0.00033	CbGpPWpGaD
Boceprevir—Vomiting—Methotrexate—systemic scleroderma	6.19e-05	0.000173	CcSEcCtD
Boceprevir—Rash—Methotrexate—systemic scleroderma	6.14e-05	0.000172	CcSEcCtD
Boceprevir—Dermatitis—Methotrexate—systemic scleroderma	6.13e-05	0.000172	CcSEcCtD
Boceprevir—Headache—Methotrexate—systemic scleroderma	6.1e-05	0.000171	CcSEcCtD
Boceprevir—Nausea—Methotrexate—systemic scleroderma	5.78e-05	0.000162	CcSEcCtD
Boceprevir—CMA1—Signaling Pathways—TGFB1—systemic scleroderma	5.3e-05	0.000272	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—HSPG2—systemic scleroderma	4.66e-05	0.000239	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	4.12e-05	0.000212	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—CTGF—systemic scleroderma	3.53e-05	0.000181	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—HSPG2—systemic scleroderma	3.52e-05	0.000181	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—CTGF—systemic scleroderma	2.66e-05	0.000137	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—HSPG2—systemic scleroderma	2.17e-05	0.000111	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—CTGF—systemic scleroderma	1.64e-05	8.44e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—NOS3—systemic scleroderma	1.54e-05	7.9e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—NOS3—systemic scleroderma	1.16e-05	5.96e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—NOS3—systemic scleroderma	7.14e-06	3.67e-05	CbGpPWpGaD
